GSK933776

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Alzheimer's DiseaseAtrophy, Geographic

Phase 1

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

CompletedNCT00459550

GlaxoSmithKlineAlzheimer's Disease

Start: 2007-03-12End: 2011-05-30Updated: 2017-07-21

Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

CompletedNCT01424436

GlaxoSmithKlineAlzheimer's Disease

Start: 2010-05-19End: 2011-12-08Updated: 2017-06-14

Phase 2

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

CompletedNCT01342926

GlaxoSmithKlineAtrophy, Geographic

Start: 2011-06-01End: 2016-04-01Updated: 2017-05-05

Related Papers

First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

PLoS ONE2015-03-1931 citations

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.

2014-04-0927 citations